Legend Biotech (LEGN) Net Income towards Common Stockholders (2019 - 2026)

Legend Biotech (LEGN) has 8 years of Net Income towards Common Stockholders data on file, last reported at -$55.0 million in Q1 2026.

• Quarterly Net Income towards Common Stockholders rose 45.5% year-over-year to -$55.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$248.6 million (up 18.1% YoY) and the FY2025 annual result came in at -$296.8 million, down 57.19% from the prior year.
• Net Income towards Common Stockholders fell to -$55.0 million in Q1 2026, from -$30.9 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$18.2 million in Q2 2024 to a low of -$199.1 million in Q2 2023.
• A 5-year average of -$89.4 million and a median of -$85.0 million in 2022 frame the typical range for Net Income towards Common Stockholders.
• Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders slumped 35570.18% — and 2024, when it jumped 90.86%.
• Tracing LEGN's Net Income towards Common Stockholders over 5 years: stood at -$135.9 million in 2022, then jumped by 34.83% to -$88.5 million in 2023, then jumped by 33.27% to -$59.1 million in 2024, then surged by 47.7% to -$30.9 million in 2025, then plunged by 77.99% to -$55.0 million in 2026.
• The last three Net Income towards Common Stockholders figures came in at -$55.0 million (Q1 2026), -$30.9 million (Q4 2025), and -$38.5 million (Q3 2025), per Business Quant data.